{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["61(4)"],"submitter":["Beck D"],"funding":["AbbVie"],"pubmed_abstract":["<h4>Background and objectives</h4>Elagolix is an orally active, gonadotropin-releasing hormone receptor antagonist approved for the management of endometriosis-associated pain and heavy menstrual bleeding associated with uterine fibroids. Elagolix population pharmacokinetics and factors affecting elagolix exposure in healthy women and women with endometriosis have been reported previously. The purpose of this study was to extend the population pharmacokinetics model with additional modifications to incorporate data from phase III studies of elagolix with hormonal add-back therapy in women with uterine fibroids.<h4>Methods</h4>Data from 13 clinical studies (a total of 2168 women) consisting of six phase I studies in healthy premenopausal women, four phase III studies in premenopausal women "],"journal":["Clinical pharmacokinetics"],"pagination":["577-587"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8975762"],"repository":["biostudies-literature"],"pubmed_title":["Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids."],"pmcid":["PMC8975762"],"pubmed_authors":["Beck D","Liu M","Shebley M","Degner J","Winzenborg I","Mostafa NM","Noertersheuser P"],"additional_accession":[]},"is_claimable":false,"name":"Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids.","description":"<h4>Background and objectives</h4>Elagolix is an orally active, gonadotropin-releasing hormone receptor antagonist approved for the management of endometriosis-associated pain and heavy menstrual bleeding associated with uterine fibroids. Elagolix population pharmacokinetics and factors affecting elagolix exposure in healthy women and women with endometriosis have been reported previously. The purpose of this study was to extend the population pharmacokinetics model with additional modifications to incorporate data from phase III studies of elagolix with hormonal add-back therapy in women with uterine fibroids.<h4>Methods</h4>Data from 13 clinical studies (a total of 2168 women) consisting of six phase I studies in healthy premenopausal women, four phase III studies in premenopausal women ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-05-31T21:02:15.397Z","creation":"2025-04-04T21:42:45.247Z"},"accession":"S-EPMC8975762","cross_references":{"pubmed":["34878624"],"doi":["10.1007/s40262-021-01096-w"]}}